Diana L. Donnelly-Roberts

TL;DR: It is demonstrated that selective blockade of P2X7 receptors in vivo produces significant antinociception in animal models of neuropathic and inflammatory pain.

TL;DR: 1-Benzyl-5-aryltetrazoles were discovered to be novel antagonists for the P2X(7) receptor and advanced to efficacy studies in a model of neuropathic pain where significant reversal of mechanical allodynia was observed at doses that did not affect motor coordination.

TL;DR: A novel series of 3-pyridyl ether compounds which possess subnanomolar affinity for brain nA cholinergic channel modulators and differentially activate subtypes of neuronal nAChRs are reported.

TL;DR: ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury and is likely mediated through immuno-neural interactions that affect the release of endogenous cytokines.

TL;DR: Acute activation of P2X7 receptors rapidly opens a non‐selective cation channel and sustained P2x7 receptor activation leads to the formation of cytolytic pores, mediated by downstream recruitment of hemichannels to the cell surface.